# Beta Bionics Inc. (BBNX)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $595M  
**Price:** $14.69 (+7.07%)

> Beta Bionics Inc. is a commercial-stage medical device company focused on designing, developing, and commercializing advanced solutions to improve the health and quality of life for people requiring insulin due to diabetes. Its flagship product, the iLet Bionic Pancreas, is an FDA-cleared automated insulin delivery system for treating type 1 diabetes in adults and children aged six and older. This innovative device autonomously calculates and delivers 100% of insulin doses using data from compatible continuous glucose monitors like Dexcom or FreeStyle Libre 3 Plus, eliminating the need for carb counting or manual corrections. The company offers the recently introduced Color iLet with an enhanced color screen, brighter display, and louder alerts. Beta Bionics Inc. is also advancing a Patch Pump that adheres directly to the skin without tubing, a Bihormonal iLet combining insulin and glucagon delivery, and an iLet for insulin-dependent type 2 diabetes. It maintains collaborations with Xeris Pharmaceuticals for pump-compatible glucagon and Abbott Diabetes Care for automated insulin delivery systems. Founded in 2015 and headquartered in Irvine, California, Beta Bionics Inc. serves the diabetes community through durable medical equipment and pharmacy benefit plan channels, including a Pharmacy Advantage Program offering the first 30 days free.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $100M | $56M | -$72M | -$73M | — |
| 2024 | $65M | $36M | -$45M | -$55M | — |
| 2023 | $12M | $6M | -$36M | -$44M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $329M | $41M | $288M | $32M | — |
| 2024 | $150M | $74M | -$245M | $30M | — |
| 2023 | $110M | $51M | -$203M | $27M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$51M | $5M | -$56M |
| 2024 | -$48M | $3M | -$52M |
| 2023 | -$32M | $402,000 | -$33M |

Source: [CompaniesByCap](https://companiesbycap.com/company/BBNX)